A 74-Year-Old-Man with Metastatic Prostate Cancer - Episode 4

Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

EP. 1: Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer
EP. 2: Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
EP. 3: Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials
Now Viewing
EP. 4: Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial
EP. 5: Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel
EP. 6: Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC
EP. 7: The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
EP. 8: Unmet Needs and Clinical Pearls in mCRPC